Merck's Phase 3 Trial of Subcutaneous Pembrolizumab (Keytruda) Meets Primary Endpoints

Nov 19, 2024, 11:48 AM

Merck has announced that its Phase 3 trial of an under-the-skin version of Keytruda, also known as Pembrolizumab, combined with Berahyaluronidase Alfa, has met its primary endpoints. This development is part of Merck's strategy to extend the sales of Keytruda, a leading cancer immunotherapy drug. The successful study results underscore Merck's commitment to advancing oncology research and improving treatment options for patients.